- Pappalardo F, Schulte C, Pieri M, et al. Concomitant implantation of Impella® on top of veno-arterial extracorporeal membrane oxygenation may improve survival of patients with cardiogenic shock. Eur J Heart Fail. 2017;19(3):404–412. doi:10.1002/ejhf.668.
- Lima B, Kale P, Gonzalez-Stawinski GV, et al. Effectiveness and safety of the Impella 5.0 as a bridge to cardiac transplantation or durable left ventricular assist device. Am J Cardiol. 2016;117(10):1622–1628. doi:10.1016/j.amjcard.2016.02.038.
- Lamarche Y, Cheung A, Ignaszewski A, et al. Comparative outcomes in cardiogenic shock patients managed with Impella microaxial pump or extracorporeal life support. J Thorac Cardiovasc Surg. 2011;142(1):60–65. doi:10.1016/j.jtcvs.2010.07.075.
- Shah P, Smith S, Haft JW, et al. Clinical outcomes of advanced heart failure patients with cardiogenic shock treated with temporary circulatory support before durable LVAD implant. Asaio J. 2016;62(1):20–27. doi:10.1097/MAT.0000000000000309.
- Bertoldi LF, Pappalardo F, Lubos E, et al. Bridging INTERMACS 1 patients from VA-ECMO to LVAD via Impella 5.0: de-escalate and ambulate. J Crit Care. 2020;57:259–263. doi:10.1016/j.jcrc.2019.12.028.
Baylor University Medical Center Proceedings
The peer-reviewed journal of Baylor Scott & White Health
Volume 36, 2023 - Issue 2
Case Studies
Impella 5.5 and venovenous extracorporeal membrane oxygenation as a bridge to ventricular assist device in cardiopulmonary failure
Austin KluisBaylor Scott & White The Heart Hospital, Plano, TexasCorrespondence[email protected]
https://orcid.org/0000-0001-7452-8906
, MDhttps://orcid.org/0000-0001-7452-8906, , MD, , MD, , MD & , MD